<?xml version='1.0' encoding='utf-8'?>
<document id="25571292"><sentence text="A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans."><entity charOffset="49-60" id="DDI-PubMed.25571292.s1.e0" text="simvastatin" /><entity charOffset="65-74" id="DDI-PubMed.25571292.s1.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.25571292.s1.e0" e2="DDI-PubMed.25571292.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25571292.s1.e0" e2="DDI-PubMed.25571292.s1.e1" /></sentence><sentence text="Verapamil is a calcium channel blocker commonly used in treatments of hypertension"><entity charOffset="0-9" id="DDI-PubMed.25571292.s2.e0" text="Verapamil" /><entity charOffset="15-22" id="DDI-PubMed.25571292.s2.e1" text="calcium" /><pair ddi="false" e1="DDI-PubMed.25571292.s2.e0" e2="DDI-PubMed.25571292.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25571292.s2.e0" e2="DDI-PubMed.25571292.s2.e1" /></sentence><sentence text=" Verapamil and its active metabolite, norverapamil, are known to be CYP3A4 inhibitors"><entity charOffset="1-10" id="DDI-PubMed.25571292.s3.e0" text="Verapamil" /><entity charOffset="38-50" id="DDI-PubMed.25571292.s3.e1" text="norverapamil" /><pair ddi="false" e1="DDI-PubMed.25571292.s3.e0" e2="DDI-PubMed.25571292.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25571292.s3.e0" e2="DDI-PubMed.25571292.s3.e1" /></sentence><sentence text=" Co-administration of verapamil with CYP3A4 substrates can alter the pharmacokinetics of the substrates" /><sentence text=" Simvastatin, a commonly used HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia is extensively metabolized by CYP3A4"><entity charOffset="1-12" id="DDI-PubMed.25571292.s5.e0" text="Simvastatin" /></sentence><sentence text=" Therefore, concomitant use of simvastatin and verapamil can increase simvastatin plasma concentration levels, resulting in a higher risk of rhabdomyolysis, a serious adverse drug reaction"><entity charOffset="31-42" id="DDI-PubMed.25571292.s6.e0" text="simvastatin" /><entity charOffset="47-56" id="DDI-PubMed.25571292.s6.e1" text="verapamil" /><entity charOffset="70-81" id="DDI-PubMed.25571292.s6.e2" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.25571292.s6.e0" e2="DDI-PubMed.25571292.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25571292.s6.e0" e2="DDI-PubMed.25571292.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25571292.s6.e0" e2="DDI-PubMed.25571292.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25571292.s6.e1" e2="DDI-PubMed.25571292.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25571292.s6.e1" e2="DDI-PubMed.25571292.s6.e2" /></sentence><sentence text=" Even though, pharmacokinetic data regarding the interaction between both drugs have been published, their use is limited to semiquantitative applications" /><sentence text=" Therefore, we aimed to develop a mathematical model describing drug-drug interaction between simvastatin and verapamil in humans"><entity charOffset="94-105" id="DDI-PubMed.25571292.s8.e0" text="simvastatin" /><entity charOffset="110-119" id="DDI-PubMed.25571292.s8.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.25571292.s8.e0" e2="DDI-PubMed.25571292.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25571292.s8.e0" e2="DDI-PubMed.25571292.s8.e1" /></sentence><sentence text="" /><sentence text="Eligible pharmacokinetic interaction study between simvastatin and verapamil in humans was selected from PubMed database"><entity charOffset="51-62" id="DDI-PubMed.25571292.s10.e0" text="simvastatin" /><entity charOffset="67-76" id="DDI-PubMed.25571292.s10.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.25571292.s10.e0" e2="DDI-PubMed.25571292.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25571292.s10.e0" e2="DDI-PubMed.25571292.s10.e1" /></sentence><sentence text=" The concentration-time courses from this study were digitally extracted and used for model development" /><sentence text="" /><sentence text="The drug-drug interaction between simvastatin and verapamil was modeled simultaneously with a two compartment model for verapamil with its active metabolite, norverapamil and a one compartment model for simvastatin with its active form, simvastatin hydroxy acid"><entity charOffset="34-45" id="DDI-PubMed.25571292.s13.e0" text="simvastatin" /><entity charOffset="50-59" id="DDI-PubMed.25571292.s13.e1" text="verapamil" /><entity charOffset="120-129" id="DDI-PubMed.25571292.s13.e2" text="verapamil" /><entity charOffset="158-170" id="DDI-PubMed.25571292.s13.e3" text="norverapamil" /><entity charOffset="203-214" id="DDI-PubMed.25571292.s13.e4" text="simvastatin" /><entity charOffset="237-261" id="DDI-PubMed.25571292.s13.e5" text="simvastatin hydroxy acid" /><pair ddi="false" e1="DDI-PubMed.25571292.s13.e0" e2="DDI-PubMed.25571292.s13.e0" /><pair ddi="false" e1="DDI-PubMed.25571292.s13.e0" e2="DDI-PubMed.25571292.s13.e1" /><pair ddi="false" e1="DDI-PubMed.25571292.s13.e0" e2="DDI-PubMed.25571292.s13.e2" /><pair ddi="false" e1="DDI-PubMed.25571292.s13.e0" e2="DDI-PubMed.25571292.s13.e3" /><pair ddi="false" e1="DDI-PubMed.25571292.s13.e0" e2="DDI-PubMed.25571292.s13.e4" /><pair ddi="false" e1="DDI-PubMed.25571292.s13.e0" e2="DDI-PubMed.25571292.s13.e5" /><pair ddi="false" e1="DDI-PubMed.25571292.s13.e1" e2="DDI-PubMed.25571292.s13.e1" /><pair ddi="false" e1="DDI-PubMed.25571292.s13.e1" e2="DDI-PubMed.25571292.s13.e2" /><pair ddi="false" e1="DDI-PubMed.25571292.s13.e1" e2="DDI-PubMed.25571292.s13.e3" /><pair ddi="false" e1="DDI-PubMed.25571292.s13.e1" e2="DDI-PubMed.25571292.s13.e4" /><pair ddi="false" e1="DDI-PubMed.25571292.s13.e1" e2="DDI-PubMed.25571292.s13.e5" /><pair ddi="false" e1="DDI-PubMed.25571292.s13.e2" e2="DDI-PubMed.25571292.s13.e2" /><pair ddi="false" e1="DDI-PubMed.25571292.s13.e2" e2="DDI-PubMed.25571292.s13.e3" /><pair ddi="false" e1="DDI-PubMed.25571292.s13.e2" e2="DDI-PubMed.25571292.s13.e4" /><pair ddi="false" e1="DDI-PubMed.25571292.s13.e2" e2="DDI-PubMed.25571292.s13.e5" /><pair ddi="false" e1="DDI-PubMed.25571292.s13.e3" e2="DDI-PubMed.25571292.s13.e3" /><pair ddi="false" e1="DDI-PubMed.25571292.s13.e3" e2="DDI-PubMed.25571292.s13.e4" /><pair ddi="false" e1="DDI-PubMed.25571292.s13.e3" e2="DDI-PubMed.25571292.s13.e5" /><pair ddi="false" e1="DDI-PubMed.25571292.s13.e4" e2="DDI-PubMed.25571292.s13.e4" /><pair ddi="false" e1="DDI-PubMed.25571292.s13.e4" e2="DDI-PubMed.25571292.s13.e5" /></sentence><sentence text=" The effects of verapamil and norverapamil on pharmacokinetics of simvastatin and its active form, simvastatin hydroxy acid were described by Michaelis-Menten equation"><entity charOffset="16-25" id="DDI-PubMed.25571292.s14.e0" text="verapamil" /><entity charOffset="30-42" id="DDI-PubMed.25571292.s14.e1" text="norverapamil" /><entity charOffset="66-77" id="DDI-PubMed.25571292.s14.e2" text="simvastatin" /><entity charOffset="99-123" id="DDI-PubMed.25571292.s14.e3" text="simvastatin hydroxy acid" /><pair ddi="false" e1="DDI-PubMed.25571292.s14.e0" e2="DDI-PubMed.25571292.s14.e0" /><pair ddi="false" e1="DDI-PubMed.25571292.s14.e0" e2="DDI-PubMed.25571292.s14.e1" /><pair ddi="false" e1="DDI-PubMed.25571292.s14.e0" e2="DDI-PubMed.25571292.s14.e2" /><pair ddi="false" e1="DDI-PubMed.25571292.s14.e0" e2="DDI-PubMed.25571292.s14.e3" /><pair ddi="false" e1="DDI-PubMed.25571292.s14.e1" e2="DDI-PubMed.25571292.s14.e1" /><pair ddi="false" e1="DDI-PubMed.25571292.s14.e1" e2="DDI-PubMed.25571292.s14.e2" /><pair ddi="false" e1="DDI-PubMed.25571292.s14.e1" e2="DDI-PubMed.25571292.s14.e3" /><pair ddi="false" e1="DDI-PubMed.25571292.s14.e2" e2="DDI-PubMed.25571292.s14.e2" /><pair ddi="false" e1="DDI-PubMed.25571292.s14.e2" e2="DDI-PubMed.25571292.s14.e3" /></sentence><sentence text=" Simulated simvastatin and simvastatin hydroxy acid concentrations obtained from the final model produced a good fit to the dataset from a literature"><entity charOffset="11-22" id="DDI-PubMed.25571292.s15.e0" text="simvastatin" /><entity charOffset="27-51" id="DDI-PubMed.25571292.s15.e1" text="simvastatin hydroxy acid" /><pair ddi="false" e1="DDI-PubMed.25571292.s15.e0" e2="DDI-PubMed.25571292.s15.e0" /><pair ddi="false" e1="DDI-PubMed.25571292.s15.e0" e2="DDI-PubMed.25571292.s15.e1" /></sentence><sentence text=" The final model adequately describes pharmacokinetic interaction between simvastatin and verapamil which can be helpful in prediction of rhabdomyolysis in patients with concurrent use of these drugs"><entity charOffset="74-85" id="DDI-PubMed.25571292.s16.e0" text="simvastatin" /><entity charOffset="90-99" id="DDI-PubMed.25571292.s16.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.25571292.s16.e0" e2="DDI-PubMed.25571292.s16.e0" /><pair ddi="false" e1="DDI-PubMed.25571292.s16.e0" e2="DDI-PubMed.25571292.s16.e1" /></sentence><sentence text="" /></document>